BRIEF published on 09/18/2024 at 20:05, 2 months 2 days ago Levée de fonds de 0,25 M€ par Néovacs Investissement Biotechnologie Levée De Fonds Dilution OCEANE-BSA
BRIEF published on 09/18/2024 at 20:05, 2 months 2 days ago Fundraising of €0.25 million by Néovacs Biotechnology Fundraising Investment Dilution OCEANE-BSA
PRESS RELEASE published on 09/18/2024 at 20:00, 2 months 2 days ago Levée de fonds de 0,25 MEUR Néovacs annonce une levée de fonds de 0,25 M€ via l'émission d'OCEANE-BSA pour financer la recherche sur les allergies et investir dans des projets prometteurs en Biotech et MedTech Biotech Levée De Fonds Néovacs OCEANE-BSA Recherche Allergies
BRIEF published on 08/28/2024 at 23:05, 2 months 23 days ago Ajustement de la valeur nominale : Néovacs réduit son capital Euronext Growth Réduction De Capital Santé Financière Valeur Nominale Néovacs
BRIEF published on 08/28/2024 at 23:05, 2 months 23 days ago Adjustment of the nominal value: Neovacs reduces its capital Financial Health Euronext Growth Capital Reduction Nominal Value Néovacs
PRESS RELEASE published on 08/28/2024 at 23:00, 2 months 23 days ago Ajustement de la valeur nominale Néovacs réduit la valeur nominale de son action de 0,005 € à 0,0005 € suite à une réduction de capital. La société biopharmaceutique développe des thérapies pour des maladies inflammatoires et auto-immunes Biopharmaceutique Réduction De Capital Maladies Inflammatoires Valeur Nominale Néovacs
BRIEF published on 07/04/2024 at 20:05, 4 months 16 days ago Résiliation du contrat de financement accordé à Pharnext Financement Biopharmaceutique Pharnext Résiliation Néovacs
BRIEF published on 07/04/2024 at 20:05, 4 months 16 days ago Termination of the financing contract granted to Pharnext Termination Funding Biopharmaceutical Pharnext Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 4 months 16 days ago Résiliation du contrat de financement accordé à Pharnext Résiliation du contrat de financement entre Néovacs et Pharnext, suite à des cas de défaut. Le fiduciaire demande le remboursement anticipé de 22 M€. Détails sur les sûretés en place Financement Pharnext Résiliation Néovacs Fiduciaire
BRIEF published on 06/17/2024 at 08:05, 5 months 4 days ago Néovacs collabore avec le CNRS pour développer des formulations lipidiques ARNm Collaboration Scientifique Recherche Biomédicale Formulations Lipidiques ARN Messager Néovacs CNRS
Published on 11/21/2024 at 13:00, 11 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 11 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 11 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 11 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 11 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 36 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 56 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 41 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 6 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 13 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 4 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 51 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
